Estradiol Vaginal Tablets / Suppository — Local Estrogen Tissue Support

Route: Intravaginal (tablet or suppository form).

Insert the suppository or tablet into the vaginal vault using the applicator provided or, for suppositories, by finger insertion as directed. Administration at bedtime in a supine or recumbent position optimizes mucosal contact time and limits outward displacement of the preparation. Patients should wash their hands before and after administration. The dosage form dissolves locally; it should not be swallowed. The choice between tablet and suppository form is determined by prescriber preference and patient anatomy/tolerability.

Dosing is individually determined by the prescribing clinician. Consistent with established local vaginal estrogen therapy principles:

• Initial/loading phase: Daily intravaginal insertion for 1–2 weeks to rapidly restore mucosal integrity.
• Maintenance phase: Two to three times weekly, or as prescribed, to maintain tissue support.
• The minimum effective frequency and dose should be used. Prescribers should reassess the continued need for local estrogen support at each clinical visit.

• Estradiol: Following intravaginal absorption across the vaginal mucosa, estradiol binds ERα and ERβ within squamous epithelial cells and fibroblasts. Estrogen-receptor complexes bind EREs on target gene promoters to upregulate expression of proteins governing cell proliferation, glycogen synthesis, collagen maintenance, and vascular supply to the vaginal wall. These actions restore vaginal epithelial thickness and maturation, increase mucosal secretions, lower the vaginal pH (restoring a Lactobacillus-dominant environment), and support the integrity of urethral and bladder-neck tissues, thereby improving both vulvovaginal and lower urinary tract symptoms.

Clinical Context: Local estrogen tissue support via compounded vaginal tablet or suppository is indicated in postmenopausal patients with genitourinary syndrome of menopause (GSM) — including vaginal dryness, dyspareunia, vulvovaginal burning/itching, urinary urgency, frequency, and recurrent urinary tract infections. Compounding allows dose and base customization for patients who do not tolerate commercially available formulations or who require strengths outside the commercial range.

Monitoring Considerations:

• Assess vaginal symptom improvement and vaginal maturation index at follow-up visits (8–12 weeks).
• Monitor for unexpected uterine or vaginal bleeding in women with an intact uterus.
• For patients on aromatase inhibitors, consult with the treating oncologist before initiating any local estrogen preparation.
• Periodic clinical re-evaluation is recommended to confirm continued appropriateness of local estrogen therapy.

Contraindications:

• Unexplained uterine or vaginal bleeding.
• Personal history of estrogen-dependent cancers (breast, endometrial) — individualized shared decision-making required.
• Active or prior thromboembolic events (DVT, PE, cerebrovascular accident).
• Active liver disease or hepatic insufficiency.
• Hypersensitivity to estradiol or excipients.
• Pregnancy.

Warnings & Precautions:

• Even low-dose local vaginal estrogen may have detectable systemic absorption; use the lowest effective dose for the shortest necessary duration.
• In women at high risk for breast or endometrial cancer, weigh risks and benefits with oncology input.

Drug Interactions:

• Aromatase inhibitors: potential for interference with therapeutic efficacy.
• Strong CYP3A4 inducers (rifampin, phenytoin, St. John's Wort): may reduce estradiol bioavailability.
• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): may increase estradiol levels.

Common Side Effects: Local vaginal irritation, discharge, and transient burning on insertion are the most common reports. Systemic effects (breast tenderness, headache) are uncommon with local low-dose preparations.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and moisture. Do not refrigerate unless specifically instructed by the compounding pharmacy label. Keep out of reach of children. Use before the beyond-use date (BUD) assigned by Genesis Compounding on the prescription label.

Is this prescription preparation available commercially?

The specific dose or base used in this compounded suppository or tablet may not be commercially available. Genesis Compounding prepares it as a 503A compounded preparation to meet individual patient specifications as directed by a licensed prescriber.

Tablet vs. suppository — what is the difference?

Both deliver estradiol to the vaginal mucosa locally. The choice of dosage form depends on prescriber preference, patient anatomy, and tolerability. Both dissolve in the vaginal environment; neither should be swallowed.

Should I also take systemic hormones?

Local vaginal estrogen is intended for genitourinary tissue support and is distinct from systemic hormone therapy. Whether systemic HRT is also appropriate for your symptoms (e.g., hot flashes) is a separate clinical determination made by your prescriber.

Is ongoing use safe?

Data from low-dose vaginal estrogen studies show a favorable safety profile for genitourinary use. Your prescriber will evaluate risks and benefits periodically and may adjust your dose or frequency as needed.

How soon can I expect to feel improvement?

Initial symptomatic relief from dryness and discomfort may be experienced within 2–4 weeks, with more complete tissue restoration typically apparent at 8–12 weeks of consistent use.